Company Profile
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase.
Its portfolio also includes GST-tagged and Biotinylated, Protein Substrate, and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions Activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo assay cell-based assay services which include NanoBRET TE intracellular kinase assay and split luciferase protein-protein interaction detection assay.
Additionally, it engages in developing monzosertib, an orally bioavailable small molecule inhibitor of cell division cycle 7 (CDC7) kinase that is in Phase 1 to treat various cancer cell lines
Including solid and blood cancers. Its portfolio also includes docirbrutinib, an orally bioavailable, non-covalent pan-inhibitor of wild type and mutant Bruton's tyrosine kinases for the treatment of chronic lymphocytic leukemia and B-cell malignancies, and sofnobrutinib, a non-covalent Bruton's tyrosine kinases which is in clinical development to treat inflammatory and immune disorders. Incorporated in 2003, Carna Biosciences is headquartered in Kobe, Japan.